SOPHIA GENETICS和AstraZeneca伙伴促进全球获得液体生物检验。 SOPHiA GENETICS and AstraZeneca partner to enhance global access to liquid biopsy testing.

SOPHIA GENETICS和AstraZeneca合作,在下一年向20个机构部署MSK-ACCESSE系统,以加强全球获得较少侵入性液体生物测试的机会。 SOPHiA GENETICS and AstraZeneca have partnered to enhance global access to less invasive liquid biopsy testing, deploying the MSK-ACCESS® system to 20 institutions in the next year. 这一协作旨在补充固体组织测试,并生成真实世界数据,以支持癌症研究。 This collaboration aims to complement solid tissue testing and generate real-world data to support cancer research. 意大利的Gardant Health和Gemelli医院将建立内部液体活检服务,而Pillar Biosciences和AstraZeneca的目标是改善欧洲的分子检测. Additionally, Guardant Health and Policlinico Gemelli in Italy will establish an in-house liquid biopsy service, while Pillar Biosciences and AstraZeneca aim to improve molecular testing access in Europe.